PURPLE BIOTECH LTD.PPBT

時価総額
PER
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
2023年
12月31日
Loss for the year from continuing operations-6-28-182220
Depreciation00000
Finance expenses (income), net---0-1-
Finance income, net----2
Share-based payments13222
Total adjustments-6-10-16-20-20
Changes in other current assets01-000
Changes in trade payable1-2011
Changes in other payables-0-112-1
Changes in post-employment benefit liabilities-0-000-0
Changes in assets and liabilities, total--130
Net cash used in operating activities from continuing operation----17-20
Depreciation00000
Finance expenses (income), net---0-1-
Finance income, net----2
Share-based payments13222
Total adjustments-6-10-16-20-20
Acquisition of subsidiary, net of cash acquired (see Note 5C)----4
Acquisition of intangible asset---0-
Proceed from other investments----1
Decrease in short term deposits---2016
Acquisition of intangible asset---0-
Decrease (increase) in long term deposits---0-
Decrease in short term deposits---2016
Interest received--00-
Acquisition of fixed assets00000
Interest received----1
Net cash provided by investing activities from continuing operation---2014
Acquisition of fixed assets00000
Changes in other current assets01-000
Changes in trade payable1-2011
Changes in other payables-0-112-1
Changes in post-employment benefit liabilities-0-000-0
Changes in assets and liabilities, total--130
Net cash used in operating activities from continuing operation----17-20
Proceeds from issuance of ADSs328112
ADS issuance expenses paid--00-
ADS issuance expenses paid----0
Proceeds from issuance of ADSs, warrants and prefunded warrants----5
Warrants issuance expenses paid----1
Proceeds from exercise of warrant--1--
Repayment of lease liability00000
Interest paid00000
Net cash provided by financing activities from continuing operation--215
Net cash used in operating activities from continuing operation----17-20
Acquisition of subsidiary, net of cash acquired (see Note 5C)----4
Acquisition of intangible asset---0-
Proceed from other investments----1
Decrease in short term deposits---2016
Acquisition of intangible asset---0-
Decrease (increase) in long term deposits---0-
Decrease in short term deposits---2016
Interest received--00-
Acquisition of fixed assets00000
Interest received----1
Net cash provided by investing activities from continuing operation---2014
Acquisition of fixed assets00000
Net cash provided by investing activities from continuing operation---2014
Net increase (decrease) in cash and cash equivalents---04-1
Proceeds from issuance of ADSs328112
ADS issuance expenses paid--00-
ADS issuance expenses paid----0
Proceeds from issuance of ADSs, warrants and prefunded warrants----5
Warrants issuance expenses paid----1
Proceeds from exercise of warrant--1--
Repayment of lease liability00000
Interest paid00000
Net cash provided by financing activities from continuing operation--215
Net cash provided by financing activities from continuing operation--215
Effect of translation adjustments on cash and cash equivalents00-0-00
Net increase (decrease) in cash and cash equivalents---04-1
Effect of translation adjustments on cash and cash equivalents00-0-00